Exact Sciences (EXAS) is slated to report its fourth-quarter and full-year 2023 earnings on Feb 21.Exact Sciences is a leading cancer diagnostics company, which focuses on the development of new and innovative tests for the prevention of cancer through early detection. The company’s portfolio of FDA-approved flagship cancer screening and diagnostics tests includes Cologuard and Oncotype DX.Let us see how things have shaped up for the quarter to be reported.Factors to ConsiderExact Sciences reports its reven ...

The market expects Exact Sciences (EXAS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2023 webcast & conference call details Date: Wednesda ...

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.The ability to identify stocks that are likely to ...

Key PointsExact Sciences develops cancer detection and diagnostic tests like Cologuard.Hologic reported Q3 2023 17.5% organic revenue growth, excluding COVID-related revenues, which resulted in a drop of 5.5% year-over-year as normalization continues.Amicus Therapeutics develops treatments for rare diseases like Fabry and Pompe disease.5 stocks we like better than Exact SciencesThe new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous fo ...

Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5-$647.5 million, an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0-$487.0 million and Precision Oncology revenue of $159.5-$160.5 million Expects total full-year 2023 revenue of $2.50 billion and 2024 revenue of ...

MADISON, Wis., Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San FranciscoPresentation followed by Q&A on Monday, January 8, 2024 at 2:15 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. ...

We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding its treatment. Third-quarter 2023 earnings call November 1, 2023 EXACT SCIENCES 1 Safe harbor and non-GAAP disclosures This pre ...

Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Kevin Conroy - Chairman, Chief Executive Officer Jeff Elliott - Chief Financial Officer Everett Cunningham - Chief Commercial Officer Erik Holznecht - Manager, Investor Relations Conference Call Participants Catherine Schulte - Baird Brandon Couillard - Jefferies Derik de Bruin - Bank of America Dan Brennan - TD Cowen Andrew Brackmann - William Blair Vijay Kumar - Evercore ISI Matt Syke ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 02-0478229 (State or other jurisdiction of (I.R.S. Employer incorporati ...